ANN ARBOR, MI, United States

Nanobio Corporation

www.nanobio.com
ANN ARBOR, MI, United States
SEARCH FILTERS
Time filter
Source Type

Solodushko V.,University of South Alabama | Bitko V.,Nanobio Corporation | Fouty B.,University of South Alabama
Gene Therapy | Year: 2014

We describe novel transposon piggyBac vectors engineered to deliver transgenes as efficiently as currently available piggyBac systems, but with significantly less helper DNA co-delivered into the host genome. To generate these plasmids, we identified a previously unreported aspect of transposon biology, that the full-length terminal domains required for successful plasmid-to-chromatin transgene delivery can be removed from the transgene delivery cassette to other parts of the plasmid without significantly impairing transposition efficiency. This is achieved by including in the same plasmid, an additional helper piggyBac sequence that contains both long terminal domains, but is modified to prevent its transposition into the host genome. This design decreases the size of the required terminal domains within the delivered gene cassette of the piggyBac vector from about 1500 to just 98 base pairs. By removing these sequences from the delivered gene cassette, they are no longer incorporated into the host genome which may reduce the risk of target cell transformation. © 2014 Macmillan Publishers Limited.


Patent
Nanobio Corporation and University of Michigan | Date: 2011-06-30

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.


Patent
Nanobio Corporation | Date: 2015-09-24

The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.


Patent
Nanobio Corporation | Date: 2016-07-06

The present disclosure relates to nanoemulsion vaccine compositions and methods of making and using the same. The disclosed compositions and methods provide a means of treating, preventing, or protecting an individual from anthrax exposure or poisoning.


The present disclosure relates to buffer-stabilized anthrax recombinant protective antigen (rPA) compositions and methods of making the same. The disclosed compositions and methods provide a means of stabilizing and preserving rPA in such a way that the protein maintains its native conformation and structure, maintains its immunological activity, and prevents aggregation.


Patent
Nanobio Corporation | Date: 2016-07-06

The present disclosure relates to buffer-stabilized protein compositions and methods of making the same. The disclosed compositions and methods provide a means of stabilizing and preserving proteins or peptides in such a way that the proteins or peptides maintain their native conformation and structure, maintain biological activity, and prevent aggregation.


Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.


Patent
Nanobio Corporation and University of Michigan | Date: 2013-09-30

The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of administering the same (e.g., via a heterologous prime/boost protocol (e.g., utilizing the same nanoemulsion in each the prime and boost administrations)) to induce immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.


Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.


Patent
Nanobio Corporation | Date: 2016-05-25

The present invention relates to methods for including an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.

Loading Nanobio Corporation collaborators
Loading Nanobio Corporation collaborators